From here is the main content.

Corporate Information

Corporate Information

In 1921 our company succeeded in formulating "Polytamin," an amino acid preparation that was a breakthrough invention for the time, and later in 1951, succeeded in producing a gamma globulin preparation from plasma by ethanol fractionation for the first time in Japan. Since then, our company has strengthened its business foundation as a pioneer in the field of "intravenous fluids for nutrition" and "plasma fractionation products," and it has firmly established its position in this specialized field.

Now, as a group company of the Takeda Pharmaceutical Group (consolidated company group), which is the leading pharmaceutical company in Japan, Nihon Pharmaceutical Co., Ltd. continues to grow as a unique company specializing mainly in the field of "plasma fractionation products," as well as in the fields of "gastrointestinal medications" and "disinfectants," etc. (as a "Basic & Niche Drug Pharma [pharmaceutical company]").
Our products are distributed by the strong sales network of Takeda Pharmaceutical and delivered to patients treated at university hospitals and other hospitals or clinics across Japan, as well as to consumers, and they are an important contribution to medical treatment.

Our major product is "Kenketsu GLOVENIN-I for I.V. Injection," a human normal immunoglobulin for intravenous administration. In addition to "severe infections" and "Kawasaki disease" as its major indications, it was approved for the additional indications of "chronic inflammatory demyelinating polyneuropathy (CIDP)," an intractable disease in the field of neurology, in 1999 and "pemphigus," an intractable disease in the field of dermatology, in 2008. Moreover, this product was approved for the treatment of "Stevens-Johnson syndrome (SJS)" and "toxic epidermal necrolysis (TEN)" in July 2014 and "bullous pemphigoid" in November 2015, as the first drug approved in Japan with the indications of these intractable diseases in the field of dermatology, making a great contribution to the treatment of patients who are suffering from these intractable diseases.

"MINCLEA Spraying Solution 0.8% for Endoscopy," which was approved in October 2010, is the world’s first gastric peristalsis inhibitor that can be directly sprayed into the stomach through the forceps channel of an endoscope as a new route of administration. It has greatly changed the conventional pretreatment for endoscopy and has provided a new option for clinical settings. In addition, it was approved in February 2013 for use during not only endoscopy but also endoscopic treatment, and it is expected to improve the quality of life (QOL) of a greater range of patients who undergo an endoscopic examination or treatment and to be of help when making a correct endoscopic diagnosis or performing an endoscopic treatment.

We will continue to contribute to the promotion of people’s health through research, development, manufacturing, and marketing of excellent drug products and drug-related products now and in the future.

Polytamin
Polytamin

In 1923, "Polytamin," the first amino acid oral liquid in Japan, was introduced by Dr. Thomas, the Dean of the Faculty of Pharmacy, Berlin University as an "extremely valuable product that possesses physiological conditions" in the Apotheker Zeitung published in the United States. Polytamin attracted worldwide attention.

Kenketsu GLOVENIN-I for I.V. Injection
Kenketsu GLOVENIN-I for I.V. Injection

MINCLEA Spraying Solution 0.8% for Endoscopy
MINCLEA Spraying Solution 0.8% for Endoscopy

Corporate Philosophy

We contribute to the promotion of people’s health through research, development, manufacturing, and marketing of excellent drug products and drug-related products.

Three Management Principles

  1. Striving for innovation
  2. Prioritized/efficiency-focused activities
  3. Strict compliance with laws, regulations, and corporate ethics